Evidence map›Paper›PMID 39312047›Full record

ArticleBiogerontology2024

Screening the active ingredients of plants via molecular docking technology and evaluating their ability to reduce skin photoaging.

Shiqian Zheng, Rongrong Deng, Gengjiu Huang, Zhiwen Ou, Zhibin Shen

Abstract read
PubMed Publisher
In one paragraph

Article in Biogerontology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shiqian ZhengGuangdong Botanical Beauty Care Biotechnology Co., Ltd, Guangzhou, China.
Rongrong DengGuangdong Botanical Beauty Care Biotechnology Co., Ltd, Guangzhou, China.
Gengjiu HuangGuangdong Botanical Beauty Care Biotechnology Co., Ltd, Guangzhou, China.
Zhiwen OuGuangdong Botanical Beauty Care Biotechnology Co., Ltd, Guangzhou, China.
Zhibin ShenGuangdong Botanical Beauty Care Biotechnology Co., Ltd, Guangzhou, China. szb8113@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The active ingredients of plants were screened by molecular docking technology and the result were verified. According to the verification results of molecular docking, the five active ingredients were combined in equal proportions to form a compound drug. In the HaCaT photoaging model, the effects of the compound drug on antioxidant and senescence-associated secretory phenotype (SASP) factors of the NF-κB and MAPK pathways were studied via SOD and MDA kits, DCFH-DA fluorescent probes and ELISA. In the skin photoaging model, the effects of the compound drug on antioxidants and the SASP factors of the NF-κB and MAPK pathways were studied via SOD, MDA, and CAT kits and ELISA. The results revealed that the compound drug increased SOD activity, decreased the MDA content and intracellular ROS, inhibited IL-6 in the NF-κB pathway, and inhibited MMP-1 and collagen I in the MAPK pathway. The results of HE, Masson and Victoria blue skin staining revealed that the compound drug inhibited abnormal thickening of the epidermis, abnormal breaking and accumulation of collagen fibers and elastic fibers, and maintained their orderly arrangement. Moreover, the results revealed that the compound drug increased SOD, CAT and collagen I, and reduced the MDA content, the SASP factors IL-6 and TNF-α of the NF-κB pathway, and the SASP factors MMP-1 of the MAPK pathway. The above results indicate that the active ingredients of the compound drug screened by molecular docking have the potential to reduce skin photoaging.

Indexed as

Molecular Docking SimulationSkin AgingAntioxidantsHaCaT CellsHumansMAP Kinase Signaling SystemMatrix Metalloproteinase 1NF-kappa BPlant ExtractsSkinAntioxidantsMatrix Metalloproteinase 1NF-kappa BPlant ExtractsMAPK pathwayMolecular dockingNF-κB pathwayScreeningSkin photoaging

Identifiers

PMID39312047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.